Baird lowered the firm’s price target on DexCom (DXCM) to $105 from $115 and keeps an Outperform rating on the shares. The firm updated its model following mixed Q1 results where momentum was encouraging and the setup is good for second half 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target raised to $109 from $107 at BTIG
- DexCom price target lowered to $90 from $100 at Piper Sandler
- DexCom price target raised to $106 from $103 at Canaccord
- Dexcom Reports Strong Q1 2025 Results and Strategic Growth
- Dexcom’s Strong Q1 Performance and Strategic Initiatives Drive Buy Rating